HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Lindane lice treatment

This article was originally published in The Rose Sheet

Executive Summary

Lindane lice treatment: FDA is recommending that lindane, an insecticide used in prescription-only lice treatments, be used only as a second-line therapy in patients who have failed or are intolerant to other pediculicides. The agency's recommendation follows an investigation of charges that lindane might cause neurological damage in children. FDA concluded in an April 3 "Talk Paper" that lindane is "generally safe and effective when used according to the approved directions," but said excessive doses of lindane lotion or shampoo can be "harmful." Labeling for lindane-containing products will be adapted to reflect the recommendation. In June, the Public Citizen's Health Research Group petitioned FDA to ban lindane-containing products and to recommend OTC permethrin and pyrethrin products as alternatives...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel